Jinling Pharmaceutical Company Limited (SHE:000919)

Market Cap	4.69B +15.5%
Revenue (ttm)	3.13B -13.5%
Net Income	32.11M -62.4%
EPS	0.05 -65.6%
Shares Out	621.92M
PE Ratio	145.44
Forward PE	n/a
Dividend	0.10 (1.33%)
Ex-Dividend Date	Jul 8, 2025

Volume	6,476,400
Average Volume	11,855,357
Open	7.56
Previous Close	7.55
Day's Range	7.49 - 7.57
52-Week Range	5.90 - 8.24
Beta	0.45
RSI	44.19
Earnings Date	Mar 31, 2026

About SHE:000919

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis, etc., as well as cardiovascular and cerebrovascular diseases; Sulifei ferrous aluminate tablets for the prevention and treatment of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 5,789
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000919

Financial Performance

In 2024, SHE:000919's revenue was 3.28 billion, an increase of 2.74% compared to the previous year's 3.19 billion. Earnings were 40.41 million, a decrease of -61.95%.